The neutrophil‐to‐lymphocyte ratio at the start of the second course during atezolizumab plus bevacizumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis

Sho Matoya(Toyokawa City Hospital), Yoshihito Nagura(Kasugai Municipal Hospital), Yuta Suzuki(Gifu Prefectural Tajimi Hospital), Yoshihide Kimura(Nagoya City University), Yasuhito Tanaka(Kumamoto University), Shunsuke Nojiri(Nagoya City University), Kei Fujiwara(Nagoya City University), Hiroki Koguchi(Chukyo Hospital), Atsunori Kusakabe(Japanese Red Cross Nagoya Daini Hospital), Hiromu Kondo(Nagoya Medical Center), Hiromi Kataoka(Mizuho (Japan)), Tomokatsu Miyaki(Toyokawa City Hospital), Keita Kuroyanagi(Japanese Red Cross Nagoya Daini Hospital), Hayato Kawamura(Nagoya City University), Kayoko Kuno(Nagoya City University), Takanori Suzuki(Nagoya City University), Fumihiro Okumura(Gifu Prefectural Tajimi Hospital), Kentaro Matsuura(Nagoya City University), Izumi Hasegawa(Chukyo Hospital), Atsushi Ozasa(Nagasaki Rousai Hospital), Satoshi Sobue(Kasugai Municipal Hospital)
Hepatology Research
February 1, 2023
Cited by 22


Related Papers